Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CVRx Inc CVRX

Healthcare Medical Devices
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS... see more

Recent & Breaking News (NDAQ:CVRX)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX

Accesswire May 4, 2024

CVRx Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire April 30, 2024

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

GlobeNewswire April 16, 2024

CVRx announces availability of additional data supporting long-term benefits of Barostim

GlobeNewswire April 15, 2024

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

GlobeNewswire January 31, 2024

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire January 25, 2024

CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024

GlobeNewswire January 11, 2024

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans

GlobeNewswire January 8, 2024

CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 27, 2023

CVRx receives FDA approval for expanded labeling of Barostim

GlobeNewswire December 26, 2023

CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 15, 2023

CMS Increases Outpatient Payment for Barostim Procedure

GlobeNewswire November 3, 2023

CVRx Reports Third Quarter 2023 Financial and Operating Results

GlobeNewswire October 26, 2023

CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023

GlobeNewswire October 12, 2023

CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire July 27, 2023

CVRx Reports Second Quarter 2023 Financial and Operating Results

GlobeNewswire July 25, 2023

CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023

GlobeNewswire July 11, 2023

CVRx Set to Join Russell 2000 & 3000 Indexes

GlobeNewswire June 22, 2023

CVRx to Present at the William Blair 43rd Annual Growth Stock Conference

GlobeNewswire May 25, 2023

CVRx Reports First Quarter 2023 Financial and Operating Results

GlobeNewswire April 27, 2023